Evidence map›Paper›PMID 34703838›Full record

ArticleMolecular therapy. Methods & clinical development2021

Minimal impact of ZAP on lentiviral vector production and transduction efficiency.

Helin Sertkaya, Laura Hidalgo, Mattia Ficarelli, Dorota Kmiec, Adrian W Signell, Sadfer Ali, Hannah Parker, Harry Wilson, Stuart J D Neil, Michael H Malim and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Helin SertkayaDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Laura HidalgoDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Mattia FicarelliDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Dorota KmiecDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Adrian W SignellDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Sadfer AliCell & Gene Therapy Platform, Medicinal Science and Technology, GSK, Stevenage SG1 2NY, UK.
Hannah ParkerDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Harry WilsonDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Stuart J D NeilDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Michael H MalimDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
Conrad A VinkCell & Gene Therapy Platform, Medicinal Science and Technology, GSK, Stevenage SG1 2NY, UK.
Chad M SwansonDepartment of Infectious Diseases, King's College London, London SE1 9RT, UK.
King's College London · GBAge UK · GB

Funding

Medical Research Council MC_PC_15068Medical Research Council MR/M019756/1Medical Research Council MR/S000844/1Wellcome Trust 207442/Z/17/Z
6 · The paper itself

Abstract

The antiviral protein ZAP binds CpG dinucleotides in viral RNA to inhibit replication. This has likely led to the CpG suppression observed in many RNA viruses, including retroviruses. Sequences added to retroviral vector genomes, such as internal promoters, transgenes, or regulatory elements, substantially increase CpG abundance. Because these CpGs could allow retroviral vector RNA to be targeted by ZAP, we analyzed whether it restricts vector production, transduction efficiency, and transgene expression. Surprisingly, even though CpG-high HIV-1 was efficiently inhibited by ZAP in HEK293T cells, depleting ZAP did not substantially increase lentiviral vector titer using several packaging and genome plasmids. ZAP overexpression also did not inhibit lentiviral vector titer. In addition, decreasing CpG abundance in a lentiviral vector genome did not increase its titer, and a gammaretroviral vector derived from murine leukemia virus was not substantially restricted by ZAP. Overall, we show that the increased CpG abundance in retroviral vectors relative to the wild-type retroviruses they are derived from does not intrinsically sensitize them to ZAP. Further understanding of how ZAP specifically targets transcripts to inhibit their expression may allow the development of CpG sequence contexts that efficiently recruit or evade this antiviral system.

Indexed as

HIV-1lentiviral vectorretroviral vectorZAPZC3HAV1zinc-finger antiviral protein

Identifiers

PMID34703838
PMCPMC8517000
OpenAlexW3197702573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.